BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 20403930)

  • 1. Systematic evidence review of newborn screening and treatment of severe combined immunodeficiency.
    Lipstein EA; Vorono S; Browning MF; Green NS; Kemper AR; Knapp AA; Prosser LA; Perrin JM
    Pediatrics; 2010 May; 125(5):e1226-35. PubMed ID: 20403930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic neonatal screening for severe combined immunodeficiency and severe T-cell lymphopenia: Analysis of cost-effectiveness based on French real field data.
    Clément MC; Mahlaoui N; Mignot C; Le Bihan C; Rabetrano H; Hoang L; Neven B; Moshous D; Cavazzana M; Blanche S; Fischer A; Audrain M; Durand-Zaleski I
    J Allergy Clin Immunol; 2015 Jun; 135(6):1589-93. PubMed ID: 25840725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of newborn screening for severe combined immunodeficiency.
    Van der Ploeg CPB; Blom M; Bredius RGM; van der Burg M; Schielen PCJI; Verkerk PH; Van den Akker-van Marle ME
    Eur J Pediatr; 2019 May; 178(5):721-729. PubMed ID: 30805731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fiscal implications of newborn screening in the diagnosis of severe combined immunodeficiency.
    Kubiak C; Jyonouchi S; Kuo C; Garcia-Lloret M; Dorsey MJ; Sleasman J; Zbrozek AS; Perez EE
    J Allergy Clin Immunol Pract; 2014; 2(6):697-702. PubMed ID: 25439359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The case for severe combined immunodeficiency (SCID) and T cell lymphopenia newborn screening: saving lives…one at a time.
    Quinn J; Orange JS; Modell V; Modell F
    Immunol Res; 2020 Feb; 68(1):48-53. PubMed ID: 32128663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential costs and benefits of newborn screening for severe combined immunodeficiency.
    McGhee SA; Stiehm ER; McCabe ER
    J Pediatr; 2005 Nov; 147(5):603-8. PubMed ID: 16291349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newborn screening for severe combined immune deficiency (technical and political aspects).
    Kobrynski L
    Curr Opin Allergy Clin Immunol; 2015 Dec; 15(6):539-46. PubMed ID: 26485096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and economic aspects of newborn screening for severe combined immunodeficiency: DEPISTREC study results.
    Thomas C; Durand-Zaleski I; Frenkiel J; Mirallié S; Léger A; Cheillan D; Picard C; Mahlaoui N; Riche VP; Roussey M; Sébille V; Rabetrano H; Dert C; Fischer A; Audrain M
    Clin Immunol; 2019 May; 202():33-39. PubMed ID: 30946917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Societal value of newborn screening for severe combined immune deficiency in Arkansas: An economic analysis.
    Hays LH
    Public Health Nurs; 2019 Jul; 36(4):541-544. PubMed ID: 30945355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness/Cost-Benefit Analysis of Newborn Screening for Severe Combined Immune Deficiency in Washington State.
    Ding Y; Thompson JD; Kobrynski L; Ojodu J; Zarbalian G; Grosse SD
    J Pediatr; 2016 May; 172():127-35. PubMed ID: 26876279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early vs. delayed diagnosis of severe combined immunodeficiency: a family perspective survey.
    Chan A; Scalchunes C; Boyle M; Puck JM
    Clin Immunol; 2011 Jan; 138(1):3-8. PubMed ID: 21035402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population-based newborn screening for severe combined immunodeficiency: steps toward implementation.
    Puck JM;
    J Allergy Clin Immunol; 2007 Oct; 120(4):760-8. PubMed ID: 17931561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of 15-year severe combined immunodeficiency in the Netherlands: towards newborn blood spot screening.
    de Pagter AP; Bredius RG; Kuijpers TW; Tramper J; van der Burg M; van Montfrans J; Driessen GJ;
    Eur J Pediatr; 2015 Sep; 174(9):1183-8. PubMed ID: 25875249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inclusion of ADA-SCID in expanded newborn screening by tandem mass spectrometry.
    la Marca G; Giocaliere E; Malvagia S; Funghini S; Ombrone D; Della Bona ML; Canessa C; Lippi F; Romano F; Guerrini R; Resti M; Azzari C
    J Pharm Biomed Anal; 2014 Jan; 88():201-6. PubMed ID: 24076575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs associated with treatment of severe combined immunodeficiency-rationale for newborn screening in Sweden.
    Gardulf A; Winiarski J; Thorin M; Heibert Arnlind M; von Döbeln U; Hammarström L
    J Allergy Clin Immunol; 2017 May; 139(5):1713-1716.e6. PubMed ID: 28012934
    [No Abstract]   [Full Text] [Related]  

  • 16. [Neonatal screening of severe combined immunodeficiencies].
    Thomas C; Mirallié S; Pierres C; Dert C; Clément MC; Mahlaoui N; Durand-Zaleski I; Fischer A; Audrain M;
    Arch Pediatr; 2015 Jun; 22(6):646-52. PubMed ID: 25896629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe Combined Immunodeficiency Disorders.
    Chinn IK; Shearer WT
    Immunol Allergy Clin North Am; 2015 Nov; 35(4):671-94. PubMed ID: 26454313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Decade Experience on Severe Combined Immunodeficiency Phenotype in Oman, Bridging to Newborn Screening.
    Al Sukaiti N; Ahmed K; Alshekaili J; Al Kindi M; Cook MC; Farsi TA
    Front Immunol; 2020; 11():623199. PubMed ID: 33519828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID).
    Chan K; Davis J; Pai SY; Bonilla FA; Puck JM; Apkon M
    Mol Genet Metab; 2011 Nov; 104(3):383-9. PubMed ID: 21810544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TREC Based Newborn Screening for Severe Combined Immunodeficiency Disease: A Systematic Review.
    van der Spek J; Groenwold RH; van der Burg M; van Montfrans JM
    J Clin Immunol; 2015 May; 35(4):416-30. PubMed ID: 25893636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.